Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.43 |
| ▸ | FEN1 | P39748 | 10/20 | 0.43 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925790 | 1.00 | KDM1A (0.43) | KDM1AALOX5APFEN1FYNPDCD1 | |
| SCHEMBL26512732 | 0.83 | KDM1A (0.41) | KDM1AALOX5APFEN1PDCD1CD274 | |
| SCHEMBL29686380 | 0.81 | FYN (0.43) | ALOX5APFEN1FYNTGFBR1MGAM | |
| SCHEMBL23980135 | 0.81 | FYN (0.43) | ALOX5APFEN1FYNTGFBR1MGAM | |
| SCHEMBL28952907 | 0.78 | KDM1A (0.41) | KDM1AFYNTGFBR1 | |
| SCHEMBL24899855 | 0.77 | FYN (0.44) | ALOX5APFEN1FYNTGFBR1 | |
| SCHEMBL24498490 | 0.77 | ALOX5AP (0.43) | ALOX5APFEN1FYNGAA | |
| SCHEMBL27295955 | 0.76 | SMN1; SMN2 (0.47) | TGFBR1GAATDO2 | |
| SCHEMBL30392625 | 0.76 | MAPK1 (0.47) | ALOX5APFEN1TGFBR1GAA | |
| SCHEMBL24899905 | 0.76 | TYK2 (0.38) | KDM1AALOX5APFEN1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-116283954-A | Hydroxamate compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-114901656-B | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-4136073-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Gossamer Bio Services, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115702145-A | Substituted pyridines for the treatment of inflammatory diseases | 戈萨默生物服务公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-114901656-A | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYK2, WEE2, WEE1 | KDM1A 312/4885ALOX5AP 1962/4885FEN1 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.